LNP

Targeted Immunotherapy in Oncology Market Research Report 2021: Development of New Targeted Immunotherapies, Particularly Those that Deliver Therapeutic DNA and Proteins - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 3:06pm

This research service investigates technologies that propel the development of new targeted immunotherapies, particularly those that deliver therapeutic DNA and proteins.

Key Points: 
  • This research service investigates technologies that propel the development of new targeted immunotherapies, particularly those that deliver therapeutic DNA and proteins.
  • Regarding technology, nonviral gene delivery and nucleic acid delivery offer significant advantages in terms of safety, particularly from immunogenicity and carcinogenicity.
  • The study touches on the advantages and limitations of viral and nonviral gene delivery systems for targeted immunotherapies.
  • The Strategic Imperative: Factors Creating Pressure on Growth
    2.1 Rising Success of Gene and Cell Therapies, Gene Editing Techniques, and Novel Gene Delivery Platforms

Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio

Retrieved on: 
Thursday, January 13, 2022 - 1:30pm

The intellectual property is owned by Factor Bioscience (Factor) and exclusively licensed to Brooklyn for various fields of therapeutic use.

Key Points: 
  • The intellectual property is owned by Factor Bioscience (Factor) and exclusively licensed to Brooklyn for various fields of therapeutic use.
  • We believe that the newly issued patents reflect the exceptional and innovative work in advancing mRNA-based technologies conducted by our partners at Factor Bioscience.
  • Moreover, there are greater than 60 pending patent applications which provide the opportunity for further broadening the scope of technology controlled by Brooklyn for developing transformative regenerative medicines."
  • We do not assume any obligation to update any forward-looking statement, except as required by law.

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022 - 1:26am

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

Retrieved on: 
Monday, January 10, 2022 - 6:00pm

The agreement will see the two companies collaborate to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer.

Key Points: 
  • The agreement will see the two companies collaborate to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer.
  • Under the terms of the agreement, Carisma will receive a $45 million up-front cash payment and an investment by Moderna in the form of a $35 million convertible note.
  • Carisma will be responsible for the discovery and optimization of development candidates while Moderna will lead the clinical development and commercialization of therapeutics resulting from the agreement.
  • We are delighted to see this further validated by the collaboration with Moderna and its investment in the company.

4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

Retrieved on: 
Monday, January 10, 2022 - 6:00pm

The agreement will see the two companies collaborate to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer.

Key Points: 
  • The agreement will see the two companies collaborate to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer.
  • Under the terms of the agreement, Carisma will receive a $45 million up-front cash payment and an investment by Moderna in the form of a $35 million convertible note.
  • Carisma will be responsible for the discovery and optimization of development candidates while Moderna will lead the clinical development and commercialization of therapeutics resulting from the agreement.
  • We are delighted to see this further validated by the collaboration with Moderna and its investment in the company.

ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 10, 2022 - 1:05pm

ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.
  • The presentation will be accessible to registered conference attendees.
  • ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.
  • The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.

ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

Retrieved on: 
Monday, January 10, 2022 - 1:00pm

Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the board of directors.

Key Points: 
  • Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the board of directors.
  • I am excited about furthering the development of transformative therapeutics for patients with ReCodes first-in-class LNP platform and promising genetic medicines pipeline, said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics.
  • Dr. Suliman has an exceptional track record of building and transforming small and large life science companies into leading biotechnology companies.
  • ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.

Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer

Retrieved on: 
Monday, January 10, 2022 - 12:00pm

CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer.
  • Dr. Moore has extensive management, research, translational drug development and medical affairs experience across various pharmaceutical and biotechnology companies.
  • "The OMEGA Epigenomic Programming platform has the potential to provide meaningful, disease modifying treatments to patients and families in need," said Dr. Moore.
  • As a clinician, Dr. Moore spent time at Sapir Medical Center, Meir Hospital and Edith Wolfson Medical Center.

Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics

Retrieved on: 
Monday, January 10, 2022 - 11:30am

This agreement expands our LNP capabilities and allows us to explore more projects within our existing vaccines area and new therapeutic areas where mRNA-LNP technology holds potential for success.

Key Points: 
  • This agreement expands our LNP capabilities and allows us to explore more projects within our existing vaccines area and new therapeutic areas where mRNA-LNP technology holds potential for success.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
  • Founded in February 2009, Vancouver-based Acuitas Therapeutics ( www.acuitastx.com ) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles.
  • Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines.

Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

Retrieved on: 
Monday, January 10, 2022 - 11:30am

"We are excited to begin this collaboration with Carisma to further expand our oncology pipeline with a differentiated in vivo cell-therapy approach," said Stephen Hoge, President of Moderna.

Key Points: 
  • "We are excited to begin this collaboration with Carisma to further expand our oncology pipeline with a differentiated in vivo cell-therapy approach," said Stephen Hoge, President of Moderna.
  • "Moderna's deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages," said Steven Kelly, President and Chief Executive Officer of Carisma.
  • "In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients' own cells to provide a truly personalized treatment.
  • The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.